The alloimmune response is a complex phenomenon, based on the activation of the innate and adaptive immune responses, which invariably leads to allograft rejection ([@B1]). Autocrine soluble factors, such as cytokines, are able to enhance or alternatively suppress the alloimmune response ([@B1]). While interleukin (IL)-2 and γ-interferon (IFN-γ) are among the primary mediators of the early phase of the alloimmune response ([@B2]), little is known regarding the late phase of the alloimmune response, during which alloreactive T cells are recruited to the proliferating pool, thus continuing the expansion process, while regulatory T cells (Tregs) are inhibited in exerting their suppressive function ([@B3]).

IL-21 is a cytokine produced by activated CD4^+^ T cells and NK cells that has been demonstrated to directly contribute to the orchestration of the different pathways that regulate the immune response ([@B4],[@B5]). IL-21 binds the IL-21 receptor (IL-21R) heterodimer and provides signals to CD8^+^ naïve T cells to differentiate into cytotoxic effector cells ([@B6]) and signals to CD4^+^ T cells to differentiate into Th17 cells ([@B7]--[@B9]). It was recently demonstrated that IL-21 has a role in graft-versus-host disease ([@B10],[@B11]). The basis of considering IL-21 as an important player in the alloimmune response lies in *1*) its robust role in expanding effector T cells (Teffs) ([@B6],[@B12]) and *2*) its potential inhibitory role on Tregs ([@B8],[@B9]). First, IL-21 has been shown to have a role in driving the expansion of Teffs in different disease models ([@B8],[@B13]); second, IL-21 has been previously shown to inhibit transforming growth factor (TGF)-β--driven differentiation of naïve T cells into Tregs ([@B8],[@B9]), thereby enhancing cytotoxic T-cell generation ([@B14]). Tregs control the immune response, and an IL-21--mediated impairment of Treg numbers or function may ultimately result in the impossibility of tolerance induction ([@B15]--[@B17]). Few data are available thus far on the interplay of IL-21 and Tregs in the alloimmune response ([@B10],[@B11],[@B18]).

Our aim is to study how the IL-21/IL-21R pathway interacts with FoxP3 and Tregs during alloimmune response and to explore whether IL-21 may act as an antitolerogenic cytokine, thus representing a barrier to tolerance.

RESEARCH DESIGN AND METHODS {#s5}
===========================

Mice. {#s6}
-----

The following mice were used: C57BL/6, DBA/1J, BALB/c, *Rag1^tm1Mom^*, B6-FoxP3-GFP knock-in, IL-21R^−/−^, and hIL-21-Tg ([@B15]), all in a C57BL/6 background.

Doxycycline-inducible ROSA-rtTA-IL-21-Tg mice. {#s7}
----------------------------------------------

Transgenic C57BL/6 mice expressing *mIL-21* cDNA under the control of a tetracycline-dependent promoter were crossed to ROSA-rtTA mice (see [Supplementary Data](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0880/-/DC1)). Mice were administered streptozotocin (STZ), transplanted with BALB/c islets, and treated the same day with doxycycline (2 mg/mL in drinking water until rejection).

Immunological assays. {#s8}
---------------------

Anti-CD3/anti-CD28 (anti-CD3/CD28) stimulation assay and mixed-lymphocyte reaction (MLR) assay were performed as described previously ([@B19]). In vitro assays to study generation, survival, and function of CD4^+^CD25^+^ Tregs were performed as previously described ([@B17],[@B20],[@B21]).

Protocol. {#s9}
---------

Islet-transplanted mice were treated with 400 μg mIL-21R.Fc (\>99% purity; Pfizer, Cambridge, MA) or with 400 μg i.p. of a negative-control IgG2a antibody (anti--*Eimeria tenella*) every day for 10 days and then three times per week for a total of 4 weeks ([@B22]). A group of mice was treated with mIL-21R.Fc in combination with CTLA4-Ig (Abatacept, Orencia; Bristol-Myers Squibb, Princeton, NJ) (500 μg at day 0 and 250 μg at days 2, 4, 6, 8, and 10).

Statistical analyses. {#s10}
---------------------

Data are expressed as mean ± standard error. Kaplan-Meier analysis (log-rank test) was performed for survival studies. A *P* value of \<0.05 (by two-tailed testing) was considered an indicator of statistical significance. Analyses of data were performed using an SPSS statistical package for Windows (SPSS Inc., Chicago, IL).

RESULTS {#s11}
=======

IL-21/IL-21R levels and expression after anti-CD3/CD28 stimulation and allostimulation in vitro. {#s12}
------------------------------------------------------------------------------------------------

IL-21R is highly expressed on naïve unstimulated CD4^+^, CD8^+^, and B220^+^ cells at baseline, and in contrast with previously published data ([@B23]), the percentage of IL-21R^+^ cells is unchanged on stimulated cells at day 1 and at day 3 ([Fig. 1*A* and *B*](#F1){ref-type="fig"}) (some data not shown). It is interesting that after 5 days of anti-CD3/CD28 stimulation, a reduction in the percentage of IL-21R^+^ T cells and B cells was evident compared with baseline (IL-21R^+^CD4^+^ T cells = 8.5 ± 1.7%; IL-21R^+^CD8^+^ T cells = 14.9 ± 5.6%; IL-21R^+^B220^+^ cells = 21.5 ± 14.5%; baseline vs. all, *P* \< 0.05) ([Fig. 1*C* and *D*](#F1){ref-type="fig"}). IL-21 was undetectable in the supernatant at day 1 ([Fig. 1*E*](#F1){ref-type="fig"}) and at day 3 (data not shown). However, increased levels of IL-21 in the supernatant were found at day 5 compared with day 1 (*P* \< 0.001) in the anti-CD3/CD28 stimulation assay ([Fig. 1*E* and *F*](#F1){ref-type="fig"}). When 150 ng/mL of recombinant mouse (rm)IL-21 was added in vitro, IL-21 supernatant levels were higher at day 1 compared with day 5 (*P* \< 0.001) ([Fig. 1*E* and *F*](#F1){ref-type="fig"}), possibly for rmIL-21 degradation.

![IL-21 is a cytokine of the late phase of the alloimmune response in vitro. The percentage of IL-21R^+^ CD4^+^ T cells (obtained from C57BL/6 mice) after 1 day (D1) (*A* and *B*) and 5 days (D5) (*C* and *D*) in an anti-CD3/CD28 stimulation assay in the presence of increasing concentrations of 5, 50, and 150 ng/mL rmIL-21 or mIL-21R.Fc or medium alone (no drug) (*n* = 3 experiments/conditions) was determined. IL-21R was highly expressed on CD4^+^ T cells, without any considerable changes after day 1 (*A* and *B*). At day 5, the percentage of IL-21R^+^CD4^+^ T cells was reduced compared with baseline in all conditions tested (baseline vs. all, \#*P* \< 0.05) (*C* and *D*). IL-21 levels in supernatants obtained in the anti-CD3/CD28 stimulation assay were evaluated using the Luminex assay at different time points (*n* = 3 experiments/conditions). No detectable levels of IL-21 were found in supernatants at day 1 after stimulation (*E*), whereas an increase was observed at day 5. High concentrations of mIL-21R.Fc (150 ng/mL) significantly reduced IL-21 levels (no drug vs. 150 ng/mL mIL-21R.Fc, \**P* = 0.01) (*F*). The addition of serial concentrations of rmIL-21 induced an increase in IL-21 levels at days 1 and 5 (no drug vs. rmIL-21, \**P* \< 0.05) (*E*). IFN-γ--producing CD4^+^ and CD8^+^ T cells extracted from naïve C57BL/6 mice and cultured with anti-CD3/CD28 in the presence of 5, 50, and 150 ng/mL rmIL-21 or mIL-21R.Fc or with medium alone (no drug) were evaluated using the ELISpot assay (*G* and *H*) (*n* = 3 experiments/conditions). An increase in IFN-γ--producing CD4^+^ and CD8^+^ T cells was evident on the addition of rmIL-21 (no drug vs. 50 and 150 ng/mL rmIL-21, \**P* \< 0.05) (*G* and *H*). The frequencies of IFN-γ--producing CD4^+^ and CD8^+^ T cells did not change when mIL-21R.Fc was added to the anti-CD3/CD28 assay (no drug vs. 5, 50, and 150 ng/mL mIL-21R.Fc, NS) (*G* and *H*). IFN-γ and IL-4 levels were evaluated in supernatants obtained from anti-CD3/CD28 stimulation assays at day 5 using the Luminex assay (*n* = 3 experiments/conditions). Increased levels of IFN-γ were detected in the presence of rmIL-21 (no drug vs. 150 ng/mL rmIL-21, \**P* = 0.0008), whereas IFN-γ levels were reduced in the presence of mIL-21R.Fc (no drug vs. 50 and 150 ng/mL mIL-21R.Fc, \**P* \< 0.05) (*I*). A dose-dependent increase in IL-4 levels was observed in the presence of rmIL-21 (no drug vs. 5, 50, and 150 ng/mL rmIL-21, \**P* \< 0.05), whereas no changes were evident in the presence of mIL-21R.Fc (no drug vs. 5, 50, and 150 ng/mL mIL-21R.Fc, NS) (*J*).](3223fig1){#F1}

At day 5 (but not at days 1 or 3), an overall reduction in the percentage of IL-21R^+^CD4^+^/CD8^+^/B220^+^ cells was evident ([Fig. 1*A*--*D*](#F1){ref-type="fig"}) (some data not shown) regardless of the presence of rmIL-21 or mIL-21R.Fc. The addition of mIL-21R.Fc reduced IL-21 levels in the supernatant at day 5, when IL-21 first became detectable ([Fig. 1*F*](#F1){ref-type="fig"}). Data obtained from anti-CD3/CD28 stimulation assay data were confirmed in the MLR assay as well (data not shown). To confirm that mIL-21R.Fc binds IL-21 cytokine (thus reducing IL-21 detectable levels in vitro), we added serial concentrations of mIL-21R.Fc (5, 50, and 150 ng/mL) to 150 ng/mL of rmIL-21 and evaluated IL-21 levels by Luminex assay (Millipore, Billerica, MA) at days 1, 3, and 5 after seeding. Reduced IL-21 levels were detected when rmIL-21 and mIL-21R.Fc were cocultured (i.e., IL-21 levels at day 1: no drug = 3290 ± 337 vs. mIL-21R.Fc 150 ng/mL = 1135 ± 284; *P* \< 0.05).

IL-21/IL-21R signaling enhances the T-cell response during anti-CD3/CD28 stimulation and allostimulation in vitro. {#s13}
------------------------------------------------------------------------------------------------------------------

We first challenged CD4^+^ and CD8^+^ T cells extracted from the spleens of 10-week-old C57BL/6 mice in an anti-CD3/CD28 stimulation assay with the addition of rmIL-21 or mIL-21R.Fc. Addition of rmIL-21 led to a dose-dependent increase of IFN-γ--producing CD4^+^ T cells (no drug = 70.5 ± 6.5; 5 ng/mL rmIL-21 = 91.7 ± 15.9; 50 ng/mL rmIL-21 = 104.8 ± 7.7; 150 ng/mL rmIL-21 = 110.8 ± 8.3, counted as number of IFN-γ--producing cells per 0.2 × 10^6^ total CD4^+^ T cells; no drug vs. 50 ng/mL rmIL-21 and 150 ng/mL rmIL-21, *P* \< 0.01) ([Fig. 1*G*](#F1){ref-type="fig"}) and CD8^+^ T cells ([Fig. 1*H*](#F1){ref-type="fig"}). IL-4--producing CD4^+^ T cells increased in frequency as well when rmIL-21 was added to the anti-CD3/CD28 assay, while no IL-4--producing CD8^+^ T cells were detected in this assay (data not shown). These data were confirmed in an allostimulation assay (MLR) (data not shown). Addition of mIL-21R.Fc to the anti-CD3/CD28 assay induced a decrease in IFN-γ levels and left IL-4 unchanged ([Fig. 1*I*](#F1){ref-type="fig"}), while rmIL-21 increased IFN-γ and IL-4 levels ([Fig. 1*J*](#F1){ref-type="fig"}) 5 days after stimulation.

We then evaluated the effect of genetically overexpressing or knocking down the IL-21/IL-21R pathway. We used CD4^+^ T cells obtained from *IL-21* plasmid--treated mice (injected with IL-21 pOrf plasmid) and from IL-21R^−/−^ mice (with genetic deletion of the IL-21R gene) for in vitro studies, confirming the data obtained with the rmIL-21 and mIL-21R.Fc ([Supplementary Fig. 1*A*--*D*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0880/-/DC1)).

Signaling of IL-21/IL-21R prevents Treg generation in vitro. {#s14}
------------------------------------------------------------

We performed a Treg generation assay ([@B20]) to investigate whether conversion from CD4^+^CD25^−^ cells (and, thus, FoxP3^−^) into CD4^+^FoxP3^+^ cells was affected by rmIL-21 or by the overexpression of IL-21 (through the use of hIL-21-Tg mice or *IL-21* plasmid--treated mice). In a complementary experiment, we evaluated the effect of targeting IL-21 chemically (mIL-21R.Fc) or genetically (IL-21R^−/−^ mice) in the same assays. We found a dose-dependent decrease in Treg frequency when rmIL-21 was added compared with the percentage obtained without supplementation (no drug = 33.0 ± 0.4%; 150 ng/mL rmIL-21 = 11.5 ± 0.4%; *P* \< 0.0001) ([Fig. 2*E* and *F*](#F2){ref-type="fig"}). An increase in Tregs was evident when mIL-21R.Fc was added at high concentrations only (no drug = 33.0 ± 0.4%; 150 ng/mL mIL-21R.Fc = 42.3 ± 2.8%; *P* = 0.03) ([Fig. 2*E* and *F*](#F2){ref-type="fig"}). When CD4^+^CD25^−^ cells obtained from hIL-21-Tg or *IL-21* plasmid--treated mice were used, fewer Tregs were generated as compared with when using CD4^+^CD25^−^ cells from wild type (WT) and IL-21R^−/−^ mice ([Fig. 2*G*--*L*](#F2){ref-type="fig"}).

![IL-21/IL-21R signaling and overexpression inhibits Treg generation in vitro. A Treg generation assay was performed in vitro in the presence of rmIL-21 or mIL-21R.Fc or medium alone (no drug) (*n* = 3 experiments/conditions). CD4^+^CD25^−^ cells extracted from C57BL/6 mice by magnetic microbeads were cultured with anti-CD3/CD28 antibodies, TGF-β, and increasing concentrations of rmIL-21 or mIL-21R.Fc (both at 5, 50, and 150 ng/mL) or no drug (*A* and *B*). After 4 days of culture, the percentage of CD4^+^FoxP3^+^ cells was evaluated (Tregs). Although rmIL-21 supplementation suppressed Treg generation (no drug vs. 50 and 150 ng/mL rmIL-21, \**P* \< 0.0001), the addition of mIL-21R.Fc promoted Treg expansion (no drug vs. 150 ng/mL mIL-21R.Fc, \**P* = 0.03) (*n* = 3 experiments/conditions) (*A* and *B*). Treg generation was performed with WT, hIL-21-Tg, *IL-21* plasmid--treated, and extracted IL-21R^−/−^ CD4^+^CD25^−^ T cells (*n* = 3 experiments/conditions) (*C*--*H*). A reduction of 70% compared with baseline (WT mice) in Treg generation was evident when CD4^+^ T cells were obtained from IL-21--overexpressing mice (WT vs. *IL-21* plasmid treated and hIL-21-Tg, \**P* \< 0.0001) (*C*--*F*), whereas no differences were evident when using IL-21R^−/−^ CD4^+^CD25^−^ (WT vs. IL-21R^−/−^, NS) (*G* and *H*).](3223fig2){#F2}

IL-21/IL-21R signaling inhibits Treg function and induces Treg apoptosis in vitro. {#s15}
----------------------------------------------------------------------------------

To explore whether Tregs generated in the presence of IL-21 are dysfunctional and unable to suppress Teff proliferation in vitro, CD4^+^CD25^−^ 5-(and 6)-carboxyfluorescein diacetate succinimidyl ester (CFSE)-labeled T cells obtained from WT C57BL/6.Thy1.2 mice were plated with the same number of C57BL/6.Thy1.1 Tregs generated in the presence of high concentrations (150 ng/mL) of rmIL-21 or mIL-21R.Fc or with medium alone. After 72 h of stimulation, cells were harvested, and CFSE dilution was assessed on Thy1.1-negative cells. It is interesting that an increased percentage of Teff proliferation was evident when Tregs generated in the presence of rmIL-21 were added compared with Tregs generated in the absence of drugs or with mIL-21R.Fc (no drug = 19.1 ± 0.5%; rmIL-21 = 27.7 ± 0.9%; mIL-21R.Fc = 16.1 ± 0.3%; rmIL-21 vs. all, *P* \< 0.05) ([Fig. 3*A* and *B*](#F3){ref-type="fig"}). This effect may be the result of both a reduced suppressive ability of Tregs and increased Treg apoptosis. Control CFSE-labeled CD4^+^CD25^−^ T cells stimulated in the absence of Tregs were shown to undergo robust proliferation ([Fig. 3*A* and *B*](#F3){ref-type="fig"}). To assess the mechanism through which IL-21 mediates a decrease in in vitro Treg generation, we performed a Treg maintenance assay in which GFP^+^ cells (sorted by FoxP3-GFP mice) or CD4^+^CD25^hi^ cells (obtained through cell sorting of splenocytes extracted by *IL-21* plasmid--treated or IL-21R^−/−^ mice) were plated with anti-CD3/CD28 monoclonal antibodies as well as IL-2 as a survival stimulus ([@B17]). A greater percentage of apoptotic Tregs (AnnexinV^+^/7-AAD^−^) was observed in the presence of 150 ng/mL rmIL-21 compared with Tregs cultured in the absence of any drug (no drug = 36.5 ± 0.9%; rmIL-21 = 53.4 ± 3.4%; *P* = 0.04) ([Fig. 3*C*](#F3){ref-type="fig"}). In a similar manner, IL-21 overexpressing Tregs (from *IL-21* plasmid--treated mice), but not IL-21R^−/−^ Tregs, displayed an increased apoptotic rate in the maintenance assay ([Fig. 3*D*](#F3){ref-type="fig"}). No differences in mRNA levels of Bcl2, Bcl6, Bax, Caspase 3, Caspase 8, cMyc, Fas, and FasL were detected in Tregs cultured in the presence of rmIL-21 compared with control Tregs (data not shown).

![IL-21/IL-21R signaling and overexpression reduces Treg function, Treg survival, and *FoxP3* gene transcripts without affecting methylation status. A suppression assay was performed in which CFSE-labeled CD4^+^CD25^−^ cells were stimulated with anti-CD3/CD28 antibodies. Their proliferation was then assessed in the presence of Tregs generated with high concentrations of rmIL-21 or mIL-21R.Fc (both at 150 ng/mL) or without any drug supplementation (*n* = 3 experiments/conditions) (*A* and *B*). The proliferation of stimulated CD4^+^CD25^−^ in the absence of Tregs was also evaluated (baseline vs. all, \#*P* \< 0.01) (*A* and *B*). Tregs generated in the presence of rmIL-21 displayed reduced suppression of CD4^+^CD25^−^ T-cell proliferation compared with control (no drug vs. rmIL-21, \**P* = 0.01). On the contrary, mIL-21R.Fc--induced Tregs showed an increased ability to suppress CD4^+^CD25^−^ T-cell proliferation compared with control (no drug vs. mIL-21R.Fc, \**P* = 0.04) (*A* and *B*). The apoptotic rate of FoxP3-GFP^+^ cells (extracted from FoxP3-GFP-B6 mice) plated with anti-CD3/CD28 antibodies, IL-2, and high concentrations of rmIL-21 or mIL-21R.Fc (both at 150 ng/mL) or with no drug was evaluated in a Treg maintenance assay (*n* = 3 experiments/conditions) (*C*). FoxP3-GFP^+^ cells cultured with rmIL-21 displayed a higher percentage of AnnexinV^+^/7-AAD^−^ apoptotic cells compared with those cultured with no drug (no drug vs. rmIL-21, \**P* = 0.04) (*C*). A greater percentage of apoptotic CD4^+^CD25^hi^ cells was evident when cells were obtained from *IL-21* plasmid--treated mice (WT vs. *IL-21* plasmid treated, \**P* = 0.007) (*D*), whereas no differences in apoptotic rate were evident when cells were derived from IL-21R^−/−^ mice (WT vs. IL-21R^−/−^, NS) (*n* = 3 experiments) (*D*). There were fewer *FoxP3* mRNA transcripts in Tregs generated in the presence of rmIL-21 (*n* = 3 experiments) (no drug vs. rmIL-21, \**P* = 0.01) (*E*). *FoxP3*-related gene expression (*CTLA4* \[no drug vs. *rmIL-21*, \**P* = 0.03\]; *Nrp-1* \[no drug vs. rmIL-21, \**P* = 0.01\]; and *FasL* \[no drug vs. rmIL-21, \**P* = 0.02\]) was reduced as well (*n* = 3 experiments) (*F*--*H*). To evaluate whether the IL-21 effect on Tregs was mediated by *FoxP3* DNA epigenetic reprogramming and hypermethylation, we studied the methylation status of Tregs generated in vitro in the presence of rmIL-21 or mIL-21R.Fc (both used at 150 ng/mL), and a similar percentage of methylation in two *FoxP3* DNA regions (Intron 1 and Distal Promoter) was found (no drug vs. rmIL-21 vs. mIL-21R.Fc, NS) (*n* = 3 experiments) (*I*). These data were confirmed by adding a hypomethylating agent (decitabine) to rmIL-21 in an in vitro Treg generation assay in which no recovery of *FoxP3^+^* cells was evident (NS), while decitabine (DEC) alone was able to induce an increase in Tregs (WT vs. DEC, \**P* = 0.01) (*n* = 3 experiments) (*J*).](3223fig3){#F3}

IL-21/IL-21R signaling inhibits *FoxP3* transcription without altering the *FoxP3* methylation profile in vitro. {#s16}
----------------------------------------------------------------------------------------------------------------

To better understand the interplay of IL-21/IL-21R signaling with Tregs, we performed RT-PCR studies to evaluate mRNA transcript levels of *FoxP3* and *FoxP3*-dependent genes in Tregs cultured with 150 ng/mL rmIL-21 or mIL-21R.Fc ([@B17]). RT-PCR expression studies confirmed the reduction of *FoxP3* mRNA levels (rmIL-21 = 0.2 ± 0.0 fold decrease compared with baseline, *P* = 0.01) ([Fig. 3*E*](#F3){ref-type="fig"}) and of *FoxP3*-targeted genes (*CTLA4*, *Nrp-1*, and *FasL*) in the presence of rmIL-21 ([Fig. 3*F*--*H*](#F3){ref-type="fig"}). mIL-21R.Fc did not induce any modifications in *FoxP3* and *FoxP3*-targeted gene expression. To assess whether IL-21 inhibition of TGF-β--driven differentiation of Tregs is mediated by *FoxP3* epigenetic reprogramming, we evaluated the DNA methylation profile, through pyrosequencing (see [Supplementary Data](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0880/-/DC1)), of two regions of the *FoxP3* gene (Intron 1 and Distal Promoter) known to be highly and poorly methylated, respectively, at basal conditions ([@B16]) in Tregs generated in the presence of rmIL-21 or mIL-21R.Fc or without any supplementation ([Fig. 3*I*](#F3){ref-type="fig"}). No differences were evident in the CpG base pair percentage in the Intron 1 region (mainly hypermethylated) or the Distal Promoter region (mainly hypomethylated) regardless of rmIL-21 or mIL-21R.Fc presence ([Fig. 3*I*](#F3){ref-type="fig"}).

Further confirmation of a non-*FoxP3* methylation--mediated mechanism of IL-21 action was sought by examining the ability of decitabine or 5-Aza-2′-deoxycytidine (a DNA hypomethylating agent), to promote Treg generation in the presence of rmIL-21 ([@B24]). As previously shown ([@B24]), treatment with decitabine alone was able to induce Treg generation (Δ-percentage compared with no drug: no drug = 100.0 ± 17.7% vs. decitabine = 180.3 ± 17.3%; *P* = 0.01) ([Fig. 3*J*](#F3){ref-type="fig"}). Decitabine was, however, unable to increase CD4^+^FoxP3^+^ cells in the presence of rmIL-21 (Δ-percentage compared with no drug: rmIL-21 = 29 ± 3.6% vs. rmIL-21 + decitabine = 26 ± 2.9%; NS) ([Fig. 3*J*](#F3){ref-type="fig"}).

IL-21/IL-21R levels and expression during the alloimmune response in vivo. {#s17}
--------------------------------------------------------------------------

We then evaluated the percentage of IL-21R^+^ T cells and B cells as well as levels of IL-21 during the alloimmune response in a murine model of islet transplantation in vivo. Islets harvested from BALB/c mice were transplanted under the kidney capsule of hyperglycemic C57BL/6 (STZ) mice and treated with mIL-21-R.Fc, treated with control antibody (anti--*E. tenella*), or left untreated. No changes in CD4^+^IL-21R^+^, CD8^+^IL-21R^+^, or B220^+^IL-21R^+^ cell percentage were evident in the spleen at days 7 and 14 after transplantation ([Fig. 4*A*--*C*](#F4){ref-type="fig"}). IL-21 serum levels analyzed at the same time points as above were not different at day 7 ([Fig. 4*D*](#F4){ref-type="fig"}) but increased at day 14 after islet transplantation in the three groups of mice ([Fig. 4*D*](#F4){ref-type="fig"}). The expression of the IL-21/IL-21R pathway was further evaluated in the graft infiltrate of untreated and mIL-21R.Fc--treated islet-transplanted mice at 7 and 14 days after islet transplantation. We found that *IL-21R* mRNA significantly increased at day 14 compared with baseline (in freshly isolated islets) and at day 7 (day 14 = 11.7 ± 2.5 fold increase compared with baseline; baseline vs. day 14, *P* = 0.04) ([Fig. 4*E*](#F4){ref-type="fig"}) in untreated mice, while a lower but not significant intraislet expression of *IL-21R* mRNA was evident 14 days after islet transplantation in mIL-21R.Fc--treated compared with untreated mice ([Fig. 4*E*](#F4){ref-type="fig"}).

![IL-21 is a cytokine of the late phase of the alloimmune response in vivo, and IL-21/IL-21R targeting promotes tolerance during the in vivo alloimmune response. The expression of IL-21R on T cells and B cells as well as IL-21 peripheral levels were analyzed in vivo during the alloimmune response in chemically induced (STZ) diabetic islet-transplanted C57BL/6 mice. IL-21R was highly expressed on CD4^+^, CD8^+^, and B220^+^ cells at baseline, and no differences were evident at the time points tested (days 7 and 14) in all groups of mice studied (*n* = 4 mice/time point) (*A*--*C*). Peripheral IL-21 levels were evaluated using the Luminex assay, which evaluated an increase in IL-21 levels at day 14 after transplant in untreated mice (*n* = 4) and mice treated with anti--*E. tenella* (*n* = 4) and mIL-21R.Fc (*n* = 4) (albeit to a lower extent in the latter two groups) compared with baseline (baseline vs. all, \**P* \< 0.05) (*D*). An increase in *IL-21R* mRNA expression in islet grafts was evident at day 14 in untreated islet-transplanted mice compared with baseline (in freshly isolated islets) (baseline vs. day 14, \**P* = 0.04) (*n* = 3) (*E*), while lower expression was evident in mice treated with mIL-21R.Fc (*E*). Untreated C57BL/6 mice rapidly rejected islets (MST of 14 days, *n* = 8) and treatment with anti--*E. tenella* led to a similar graft survival (MST of 13 days, *n* = 5) (*F*). mIL-21R.Fc treatment (*n* = 5) prolonged graft survival, leading to 20% tolerance (MST \>100 days) to islet grafts (MST: untreated = 14 days; anti--*E. tenella* treated = 13 days; mIL-21R.Fc treated = 19 days; mIL-21R.Fc treated vs. all, \**P* \< 0.05) (*F*). Treatment with CTLA4-Ig (500 μg at day 0; 250 μg at days 2, 4, 6, 8, and 10) synergized with mIL-21R.Fc treatment (*n* = 9) to further increase allograft survival compared with either mIL-21R.Fc or with CTLA4-Ig alone treatment, resulting in tolerance in 100% of mice (percentage of tolerance: CTLA4-Ig + mIL-21R.Fc treated = 100%; CTLA4-Ig treated = 55%; mIL-21R.Fc treated = 20%; CTLA4-Ig + mIL-21R.Fc vs. CTLA4-Ig treated \[\**P* = 0.01\] and vs. mIL-21R.Fc treated \[\**P* = 0.001\]) (*F*). Histological sections of the graft at day 14 and at day 100 after transplantation (*G1*--*J5*) revealed that untreated mice and mice treated with anti--*E. tenella* at day 14 displayed a complete loss of islet architecture and severe CD3^+^/B220^+^ cell infiltration of the graft, with few nested FoxP3^+^ cells and absent insulin staining (*n* = 3) (*G1*--*H5*). mIL-21R.Fc--treated mice presented preserved islet morphology with mild CD3^+^/B220^+^ cell infiltration, primarily constituted of FoxP3^+^ cells, as well as clearly detectable insulin staining (*n* = 3) (*I1*--*5*). CTLA4-Ig + mIL-21R.Fc--treated tolerant mice at day 100 (*n* = 3) displayed well-preserved islet architecture with no CD3^+^/B220^+^ cell infiltration in the graft and clear insulin staining (*J1*--*5*). H&E, hematoxylin-eosin. FoxP3^+^ and CD3^+^ cells infiltrating the graft at day 14 were evaluated using Aperio Technology. Greater FoxP3^+^-to-CD3^+^ cell ratio was evident in mIL-21R.Fc--treated mice compared with both control groups (mIL-21R.Fc treated vs. untreated and anti--*E. tenella* treated, \**P* = 0.04, *n* = 3 mice per group) (*K*). D, day. (A high-quality digital representation of this figure is available in the online issue.)](3223fig4){#F4}

Targeting IL-21/IL-21R expands intragraft Tregs and promotes tolerance in vivo. {#s18}
-------------------------------------------------------------------------------

We then tested the impact of targeting the IL-21/IL-21R axis (using the mIL-21R.Fc compound) on intragraft FoxP3^+^ cell expansion and ultimately on allograft survival and tolerance induction in a model of the alloimmune response in vivo (i.e., islet transplantation). Untreated C57BL/6 mice rapidly rejected islet allografts (mean survival time \[MST\] of 14 days, *n* = 5), and treatment with the negative control antibody anti--*E. tenella* led to similar graft survival (MST of 13 days, *n* = 5) ([Fig. 4*F*](#F4){ref-type="fig"}). mIL-21R.Fc treatment prolonged graft survival, leading to long-term tolerance, defined as MST \>100 days, in 20% of treated mice (MST: untreated = 14 days; anti--*E. tenella* treated = 13 days; mIL-21R.Fc treated = 19 days; mIL-21R.Fc treated vs. all, *P* \< 0.05) ([Fig. 4*F*](#F4){ref-type="fig"}). We therefore combined mIL-21R.Fc with CTLA4-Ig treatment (CTLA4-Ig: 500 μg at day 0; 250 μg at days 2, 4, 6, 8, and 10), with the aim of suppressing early T-cell activation (which is likely IL-21 independent) through CTLA4-Ig ([@B25]). CTLA4-Ig synergized with mIL-21R.Fc to further increase allograft survival compared with treatment with either mIL-21R.Fc or CTLA4-Ig alone, resulting in tolerance induction in 100% of mice (percentage of tolerant mice: CTLA4-Ig + mIL-21R.Fc treated = 100%; CTLA4-Ig alone treated = 55%; mIL-21R.Fc treated = 20%; CTLA4-Ig + mIL-21R.Fc treated vs. all, *P* ≤ 0.01) ([Fig. 4*F*](#F4){ref-type="fig"}). Histological sections of the grafts were analyzed at day 14 and at day 100 ([Fig. 4*G1*--*J5*](#F4){ref-type="fig"}). Mice treated with anti--*E. tenella* at day 14 after transplantation displayed a similar severe infiltration of the graft, primarily consisting of CD3^+^ and B220^+^ cells ([Fig. 4*G1*--*3* and *H1*--*3*](#F4){ref-type="fig"}), with absent insulin staining ([Fig. 4*G5* and *H5*](#F4){ref-type="fig"}) and very few islet-nested FoxP3^+^ cells ([Fig. 4*G4* and *H4*](#F4){ref-type="fig"}). Conversely, in the mIL-21R.Fc--treated group at day 14, islet morphology was still well preserved with several detectable insulin-producing cells and a mild CD3^+^ cell infiltrate, primarily made up of islet-nested FoxP3^+^ cells and very few B cells ([Fig. 4*I1*](#F4){ref-type="fig"}--[*5*](#F5){ref-type="fig"}). Islet morphology in tolerant CTLA4-Ig + mIL-21R.Fc--treated mice at 100 days after transplantation showed no T cells or B cells infiltrating the graft and a clear insulin staining ([Fig. 4*J1*](#F4){ref-type="fig"}--[*5*](#F5){ref-type="fig"}). An increase in the FoxP3^+^-to-CD3^+^ cell ratio, quantified with Aperio Technology (Vista, CA) ([@B19]), was observed at day 14 in mIL-21R.Fc--treated mice compared with both untreated mice and mice treated with anti--*E. tenella* ([Fig. 4*K*](#F4){ref-type="fig"}). We confirmed our mIL-21R.Fc data and recent data ([@B13]) by transplanting BALB/c islets into chemically induced (STZ) hyperglycemic IL-21R^−/−^ mice, and a prolongation of islet graft survival compared with WT control mice was indeed observed (MST: WT = 14 days; IL-21R^−/−^ = 17 days; *P* = 0.01; data not shown).

![IL-21/IL-21R targeting expands peripheral Tregs in vivo and regulates the alloimmune response. The effect of targeting IL-21 in the alloimmune response was analyzed in vivo in islet-transplanted mice during the pathogenesis of the alloimmune response. Splenocytes at day 14 after islet transplantation were harvested from untreated mice (*n* = 4) and mice treated with anti--*E. tenella* (*n* = 4) and mIL-21R.Fc (*n* = 4) and were analyzed by fluorescence-activated cell sorter. The percentages of CD4^+^ and CD8^+^ Teffs (CD4^+^CD44^hi^CD62L^lo^ and CD8^+^CD44^hi^CD62L^lo^ cells) were lower in the mIL-21R.Fc--treated group compared with untreated mice and mice treated with anti--*E. tenella* (mIL-21R.Fc treated vs. untreated and anti--*E. tenella* treated, \**P* \< 0.05) (*A*--*C*). The percentage of Tregs was greater in the mIL-21R.Fc--treated mice compared with untreated mice and mice treated with anti--*E. tenella* (mIL-21R.Fc treated vs. untreated and anti--*E. tenella* treated, \**P* \< 0.05) (*D* and *F*), as was the Treg-to-Teff ratio (mIL-21R.Fc treated vs. untreated and anti--*E. tenella* treated, \**P* \< 0.05) (*E*). The percentage of IFN-γ--producing cells was evaluated in an ex vivo antidonor immune response using an ELISpot assay. Splenocytes harvested at day 14 after transplant were rechallenged ex vivo with irradiated BALB/c splenocytes, and the number of IFN-γ--producing cells was evaluated. mIL-21R.Fc--treated mice (*n* = 3) showed a reduced number of IFN-γ--producing cells compared with untreated mice (*n* = 3) and mice treated with anti--*E. tenella* (*n* = 3) (mIL-21R.Fc treated vs. untreated and anti--*E. tenella* treated, \**P* \< 0.05) (*G*). The peripheral cytokine profile was studied in serum samples of the three groups of mice at day 14 after transplantation, which revealed an overall suppression of proinflammatory cytokines (IFN-γ, IL-2, IL-6, and IL-15) in the mIL-21R.Fc--treated group (mIL-21R.Fc treated \[*n* = 3\] vs. untreated \[*n* = 3\] and anti--*E. tenella* treated \[*n* = 3\], \**P* \< 0.05) (*H*).](3223fig5){#F5}

Targeting IL-21/IL-21R expands peripheral Tregs and regulates the antidonor immune response in vivo. {#s19}
----------------------------------------------------------------------------------------------------

A reduction in the percentage of peripheral CD4^+^CD44^hi^CD62L^low^ Teffs was evident in mIL-21R.Fc--treated mice at 14 days after transplant compared with mice treated with anti--*E. tenella* (controls) and untreated mice and CD8^+^CD44^hi^CD62L^low^ cells ([Fig. 5*A*--*C*](#F5){ref-type="fig"}). The percentage of peripheral CD4^+^CD25^+^FoxP3^+^ cells (Tregs) increased in mIL-21R.Fc--treated mice compared with the other two groups ([Fig. 5*D* and *F*](#F5){ref-type="fig"}), and a higher Treg-to-Teff ratio was evident in mIL-21R.Fc--treated mice as well ([Fig. 5*E*](#F5){ref-type="fig"}). Ex vivo rechallenge of splenocytes harvested at day 14 from islet-transplanted mice with donor alloantigen (i.e., BALB/c splenocytes) displayed a profound regulation of the antidonor-specific immune response in mIL-21R.Fc--treated mice, as shown by the reduction of IFN-γ--producing cells in the ELISpot assay (BD Bioscience, San Jose, CA) compared with mice treated with anti--*E. tenella* and untreated mice (IFN-γ--producing cells per 0.5 × 10^6^: untreated = 125.0 ± 11.3; anti--*E. tenella* treated = 163.8 ± 30.6; mIL-21R.Fc treated = 25.3 ± 4.9; mIL-21R.Fc treated vs. all, *P* ≤ 0.01) ([Fig. 5*G*](#F5){ref-type="fig"}). Of interest, 14 days after islet transplantation, a reshaping of the peripheral cytokine profile was evident in mIL-21R.Fc--treated mice as well, with an overall suppression of proinflammatory cytokines, as shown by the reduction of peripheral serum levels of IFN-γ, IL-2, IL-6, and IL-15 ([Fig. 5*H*](#F5){ref-type="fig"}) compared with controls and untreated mice. IL-4, IL-10, and IL-17 peripheral levels remained unchanged in response to all treatments ([Fig. 5*H*](#F5){ref-type="fig"}).

Targeting IL-21/IL-21R promotes Treg neogenesis in vivo. {#s20}
--------------------------------------------------------

We next asked whether targeting the IL-21/IL-21R axis would be capable of promoting Treg neogenesis in vivo. Thus, we tested whether mIL-21R.Fc treatment could promote the generation of FoxP3 Tregs after depletion of CD25 using an anti--CD25-Ig injection (500 μg at day −6 and at day −1 before islet transplantation). Treatment with anti--CD25-Ig completely depleted CD25^+^ cells and FoxP3^+^ cells (data not shown). Targeting of the IL-21/IL-21R axis (with mIL-21R.Fc) during anti--CD25-Ig treatment slightly prolonged islet graft survival compared with anti--CD25-Ig treatment alone (MST: anti--CD25-Ig + mIL-21R.Fc treated = 25; anti--CD25-Ig treated = 20 days; *P* = 0.04) ([Fig. 6*A*](#F6){ref-type="fig"}). Moreover, mIL-21R.Fc showed the ability to newly generate splenic CD4^+^FoxP3^+^ cells ([Fig. 6*B*](#F6){ref-type="fig"}). To verify the robustness of the tolerance induced by mIL-21R.Fc + CTLA4-Ig treatment, we recovered 1 × 10^7^ splenocytes from long-term tolerant mice at day 50 after islet transplantation and adoptively transferred them into immunodeficient C57BL/6-RAG mice that had been islet transplanted the day before with BALB/c islets. Splenocytes from rejecting islet-transplanted C57BL/6 mice were used as controls. Of interest, 100% of C57BL/6-RAG mice that were adoptively transferred with splenocytes obtained from long-term tolerant mice did not reject BALB/c islets compared with the control group, which promptly rejected BALB/c islets (MST: long-term tolerant mice = 100 days; rejecting mice = 14 days; *P* \< 0.0001) ([Fig. 6*C*](#F6){ref-type="fig"}). To evaluate whether mice were immunocompetent, we transplanted skin grafts from third-party DBA/1 J (H2^q^) donors into mIL-21R.Fc + CTLA4-Ig--treated long-term tolerant mice and into the control group of rejecting mice. Both groups of mice invariably rejected third-party skin grafts at ∼14 days after transplantation, thus confirming that mice treated with mIL-21R.Fc + CTLA4-Ig are immunocompetent ([Fig. 6*D*](#F6){ref-type="fig"}). Finally, we tested mIL-21R.Fc + CTLA4-Ig treatment in a stringent model of tolerance resistance and in which BALB/c islets were transplanted into NOD mice, confirming a prolongation of graft survival in mice treated with mIL-21R.Fc + CTLA4-Ig compared with both untreated mice and CTLA4-Ig alone--treated mice ([Fig. 6*E*](#F6){ref-type="fig"}).

![IL-21/IL-21R targeting generates new Tregs, and IL-21 inducible overexpression expands FoxP3^−^ cells in vivo. To assess whether IL-21 targeting promotes the neogenesis of FoxP3 Tregs, we pretreated C57BL/6 mice with a CD25-depleting agent (i.e., anti--CD25-Ig capable of depleting CD4^+^CD25^+^ cells) the day before mice received islets from BALB/c donors. Mice were then treated with mIL-21R.Fc or were left untreated. Mice treated with mIL-21R.Fc displayed slight prolongation in graft survival (MST: anti--CD25-Ig treated = 20 days vs. anti--CD25-Ig + mIL21-R.Fc treated = 25 days, \**P* = 0.03) (*A*) but significant neogeneration of CD4^+^FoxP3^+^ cells (\**P* = 0.005) at the day of rejection compared with untreated mice (*B*). To test the robustness of tolerance toward alloantigen, long-term tolerant splenocytes harvested from mice treated with CTLA4-Ig + mIL-21R.Fc or from rejecting mice as controls were adoptively transferred (AT) into immunodeficient C57BL/6 RAG mice 1 day after BALB/c islet transplantation (*C*). Of mice receiving splenocytes from long-term tolerant mice, 100% did not reject islet grafts, whereas all mice injected with splenocytes harvested from rejecting mice rejected islet graft with a pattern similar to naïve untreated C57BL/6 mice (MST: tolerant splenocytes = 100 days vs. rejected splenocytes = 14 days, \**P* \< 0.0001) (*C*). To test immunocompetence of long-term tolerant mice, skin grafts from third-party donors (DBA/1 J \[H2^q^\]) were transplanted into mice treated with mIL-21R.Fc + CTLA4-Ig or control rejecting mice (*D*). All mice rejected donor-derived skin grafts with the same timing, confirming that mice treated with CTLA4-Ig + mIL-21R.Fc are immunocompetent (*D*). To further test the efficacy of mIL-21R.Fc + CTLA4-Ig treatment, we performed islet transplantation in a stringent model of tolerance resistance. BALB/c islets were transplanted into spontaneously hyperglycemic NOD mice and treated with CTLA4-Ig + mIL-21R.Fc, CTLA4-Ig alone, or were left untreated. Mice treated with CTLA4-Ig + mIL-21R.Fc showed a significant prolongation of graft survival compared with both CTLA4-Ig--treated (\**P* = 0.01) and untreated mice (\**P* = 0.008) (*E*). A transgenic C57BL/6 doxycycline-inducible IL-21-Tg mouse was generated, allowing IL-21 to be induced when needed (*F*--*H*). The murine *IL-21* cDNA was subcloned into the Sal I and Xba I sites of the pTRE-Tight vector (*F*). The Xho I restriction fragment, encompassing the P~tight~ tet-responsive promoter, the *IL-21* cDNA, and the SV40 poly A sequence, was excised and used to generate IL-21-Tg founder mice on a C57BL/6 background. The location and relative size of the PCR products used to identify the Tg mice are indicated (*G*). The IL-21-Tg mice were crossed with ROSA rtTA\*M2 transgenic mice to introduce the Doxa-regulated reverse transcriptional activator. The resulting progeny were screened by PCR to identify the IL-21-Tg^+^ mice used in this study (*H*). Doxycycline-inducible IL-21-Tg mice (on a C57BL/6 background) were transplanted with BALB/c islets and administered doxycycline at day 0 to induce IL-21. At the time of rejection, doxycycline-induced mice (*n* = 5) showed an increased percentage of CD4^+^CD44^hi^CD62L^low^ cells (\**P* = 0.0009) (*I*), CD8^+^CD44^hi^CD62L^low^ cells (\**P* = 0.001) (*J*), and CD4^+^CD25^+^FoxP3^−^ cells (\**P* = 0.002) (*K*), and a reduced CD25^+^FoxP3^+^-to-CD25^+^FoxP3^−^ cell ratio (\**P* = 0.0001) (*L*) in the spleen compared with control mice (*n* = 4).](3223fig6){#F6}

IL-21/IL-21R signaling in doxycycline-inducible ROSA-rtTA-IL-21-Tg mice expands Teffs and FoxP3^−^ cells. {#s21}
---------------------------------------------------------------------------------------------------------

To confirm the paramount effect of IL-21 on FoxP3 and Treg function/survival in vivo, we generated the doxycycline-inducible ROSA-rtTA-IL-21-Tg mouse (Doxa-inducible IL-21-Tg). This transgenic C57BL/6 mouse expresses *mIL-21* cDNA in a tetracycline-responsive element composed of the *tet* operator sequence under the control of a tetracycline-controlled transcriptional activator *M2* promoter ([Fig. 6*F*--*H*](#F6){ref-type="fig"}). We then transplanted BALB/c islets into the Doxa-inducible IL-21-Tg mice, followed by daily doxycycline administration beginning from day 0 until rejection. Doxycycline-treated Doxa-inducible IL-21-Tg mice rejected the grafts with the same timing of Doxa-inducible IL-21-Tg untreated mice (MST: WT doxycycline treated = 14 days vs. Doxa-inducible IL-21-Tg untreated = 17 days, NS) (data not shown). Doxa-inducible IL-21-Tg mice treated with doxycycline showed similar percentage of CD4^+^CD25^+^FoxP3^+^ cells (data not shown), with a clear expansion of CD4^+^CD44^hi^CD62L^low^ cells ([Fig. 6*I*](#F6){ref-type="fig"}), CD8^+^CD44^hi^CD62L^low^ cells ([Fig. 6*J*](#F6){ref-type="fig"}), and CD4^+^CD25^+^FoxP3^−^ cells (Doxa-inducible IL-21-Tg untreated = 9.7 ± 1.2%; Doxa-inducible IL-21-Tg doxycycline treated = 30.8 ± 5.0%; *P* = 0.002) ([Fig. 6*K*](#F6){ref-type="fig"}).

Finally, CD4^+^CD25^+^Fox3^+^-to-CD4^+^CD25^+^FoxP3^−^ cell ratio is reduced in Doxa-treated mice compared with controls ([Fig. 6*L*](#F6){ref-type="fig"}). The absence of CD4^+^CD25^+^FoxP3^+^ cell reduction in Doxa-inducible IL-21-Tg mice observed in the acute model may be related to the fast tempo of acute rejection, which may not fit with the IL-21 role. To further clarify this issue, we have obtained long-term islet function in C57BL/6 islet-transplanted mice with CTLA4-Ig + mIL-21R.Fc, and we have then induced IL-21 by doxycycline administration 40 days after transplantation. Very few Tregs (3.7 ± 0.5%) were detected in mice 20 days after doxycycline administration, when mice started to be sick.

DISCUSSION {#s22}
==========

FoxP3^+^ Tregs play an essential role in maintaining immunological unresponsiveness to alloantigens and in suppressing the immune response ([@B26]). Herein, we propose IL-21 as an anti-FoxP3/anti-Treg cytokine of the late-phase alloimmune response that disrupts FoxP3 and alters Treg function, thereby acting as an antitolerogenic factor, thus eliciting an enhanced alloimmune response, and creating a barrier to transplant tolerance ([@B1]). In our study, IL-21 was increased in vitro after 5 days in anti-CD3/CD28 and MLR assays and in vivo 14 days after islet transplantation. IL-21R expression decreased in vitro after 5 days of stimulation and was found elevated in the graft infiltrate of rejecting untreated mice at later time points as well. Furthermore, mIL-21R.Fc (a fusion protein that prevents the binding of murine IL-21 to IL-21R) ([@B22]) is effective in vitro only in the late phase of allostimulation. These data, combined with the head-to-head comparison of IL-2 and IL-21 levels in vitro and in vivo ([Fig. 7](#F7){ref-type="fig"}), revealed that in a "physiological" alloimmune setting, IL-21 is not responsible for the early response to alloantigen (unlike IL-2), but it does exert its function in the late-phase immune response ([Fig. 7](#F7){ref-type="fig"}) ([@B27]). It is possible that IL-21 ensures the redundancy of the system, thus maintaining activation of the alloimmune response and avoiding Treg counterregulation ([Fig. 7](#F7){ref-type="fig"}). IL-21 is capable of enhancing the alloimmune response, as shown by our in vitro experiments with rmIL-21 and with *IL-21* plasmid--treated or hIL-21-Tg mice. However, it is likely that IL-21 may have a different role in the physiological alloimmune setting as a mediator of FoxP3 and of Treg dysfunction. The IL-21 interplay with Tregs was tested in vitro, using assays for Treg generation, survival, and function, during the challenge with rmIL-21 or mIL-21R.Fc, or by using hIL-21-Tg, *IL-21* plasmid--treated (which overexpress IL-21), or IL-21R^−/−^ mice. We show that TGF-β--driven conversion of CD4^+^CD25^−^ T cells (FoxP3^−^), Treg survival, and Treg suppressive function are negatively affected by rmIL-21 but positively affected by mIL-21R.Fc. Indeed, we demonstrate an inhibition of *FoxP3* and *FoxP3*-dependent gene transcripts by IL-21 ([@B28]), without evidence of IL-21--mediated epigenetic reprogramming of the *FoxP3* gene, at least at the methylation level. These data were further confirmed by the inability of the demethylating agent decitabine to rescue Tregs in the presence of rmIL-21, thus indicating that despite the fact that decitabine is a robust inducer of Tregs in vitro ([@B29]), IL-21 is more potent in inhibiting Treg generation. We therefore demonstrate that blockade of the IL-21/IL-21R axis (both chemically and genetically) during the alloimmune response in vivo promotes the expansion of intragraft and peripheral Tregs and induces tolerance when combined with CTLA4-Ig, which targets early T-cell activation and is likely IL-21 independent. We show that mIL-21R.Fc promotes FoxP3 Treg neogenesis in vivo and that the mechanism of tolerance induction is robust and transferable to nude mice. The strong effect of the combination of mIL-21R.Fc and CTLA4-Ig on alloimmunity does not apply to NOD mice, which show the coexistence of strong allo- and autoimmune anti-islet responses ([@B30]). Autoimmune response is mediated by several different cell types (e.g., B cells, NK cells, macrophages, and Th17 cells), which may not be targeted by mIL-21R.Fc, but this aspect will be further investigated. Finally, we provide evidence that IL-21 promotes in vivo FoxP3^−^ cell expansion. In fact, in our islet-transplanted Doxa-inducible ROSA-rtTA-IL-21-Tg mice ([@B31],[@B32]), in which IL-21 is induced by doxycycline administration, both CD4^+^ and CD8^+^ activated/effector cells were found increased compared with controls, while CD25^+^FoxP3^+^-to-CD25^+^FoxP3^−^ cell ratio was reduced. Furthermore, long-term tolerant mice overexpressing IL-21 (by doxycycline administration) showed very few Tregs. Taken together, our data suggest that IL-21 is a potent inhibitor of the FoxP3 Treg chain and an inducer of Teffs and that the blockade of the IL-21/IL-21R pathway may induce a more tolerogenic environment.

![IL-21 acts as an antitolerogenic cytokine of the late phase of alloimmune response. In the early phase of the alloimmune response, antigen-presenting cells activate T cells through two signals. Proinflammatory cytokines (i.e., IL-2) are locally released, leading to alloreactive T-cell proliferation and destruction of the graft (D0 vs. all, \**P* \< 0.01). In the late phase of the alloimmune response, Teffs release IL-21, thus ablating FoxP3^+^ Tregs, reducing *FoxP3* gene transcripts, decreasing Treg generation and Treg suppressive properties, increasing Treg apoptosis, and inducing Teff expansion (D5 and D14 vs. all, \**P* \< 0.01). D, day. DC, dendritic cells. (A high-quality color representation of this figure is available in the online issue.)](3223fig7){#F7}

We posit that IL-21, together with other recently identified cytokines ([@B33]--[@B35]), is part of a network of antitolerogenic cytokines that through induction of Treg apoptosis or dysfunction, could represent a barrier to allograft tolerance. We thus posit that blockade of the IL-21/IL-21R pathway should be a precondition for many tolerogenic protocols in transplantation. Our strategy may be relevant in controlling acute as well as chronic rejection, which causes delayed islet graft loss ([@B36]--[@B38]) and represents a barrier for long-term allograft survival ([@B39],[@B40]), since it abrogates T-cell activation in the early phase of posttransplant alloimmune response (with CTLA4-Ig) and expands/induces Tregs in the late phase (with IL-21 antagonist). We thus propose to start both drugs at the day of transplantation, discontinuing CTLA4-Ig treatment later on and prolonging the administration of IL-21 antagonist.

This article contains Supplementary Data online at <http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0880/-/DC1>.
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